Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model

Vaccine

Volumn 33, Issue 46, 2015, Pages 6277-6281

  Safarchi, Azadeh ^a   Octavia, Sophie ^a   Luu, Laurence Don Wai ^a   Tay, Chin Yen ^b   Sintchenko, Vitali ^c,d   Wood, Nicholas ^e   Marshall, Helen ^f   McIntyre, Peter ^e   Lan, Ruiting ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d University of Sydney   (Australia)

^e CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^f UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Acellular pertussis vaccine; B. pertussis; Mixed infection; Mouse model; Pertactin negative

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; PERTACTIN; BORDETELLA VIRULENCE FACTOR; OUTER MEMBRANE PROTEIN; PERTUSSIS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUSTRALIA; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL STRAIN; BORDETELLA PERTUSSIS; CONTROLLED STUDY; FEMALE; FITNESS; GROWTH CURVE; GROWTH RATE; IMMUNIZATION; IN VIVO STUDY; MIXED INFECTION; MOUSE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; RESPIRATORY SYSTEM; ANIMAL; BAGG ALBINO MOUSE; COINFECTION; DISEASE MODEL; GENETIC SELECTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; WHOOPING COUGH;

ANIMALS; AUSTRALIA; BACTERIAL OUTER MEMBRANE PROTEINS; BORDETELLA PERTUSSIS; COINFECTION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE, INBRED BALB C; PERTUSSIS VACCINE; SELECTION, GENETIC; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 84946593280     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.064     Document Type: Article

References (34)

1. Tan T., Dalby T., Forsyth K., Halperin S.A., Heininger U., Hozbor D., et al. Pertussis across the globe: recent epidemiologic trends from 2000-2013. Pediatr Infect Dis J 2015.
2. Mattoo S., Cherry J.D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005, 18:326-382.
3. Godfroid F., Denoel P., Poolman J. Are vaccination programs and isolate polymorphism linked to pertussis re-emergence. Expert Rev Vaccines 2005, 4:757-778.
4. Petersen R.F., Dalby T., Dragsted D.M., Mooi F., Lambertsen L. Temporal trends in Bordetella pertussis populations, Denmark, 1949-2010. Emerg Infect Dis 2012, 18:767-774.
5. Kurniawan J., Maharjan R.P., Chan W.F., Reeves P.R., Sintchenko V., Gilbert G.L., et al. Bordetella pertussis clones identified by multilocus variable-number tandem-repeat analysis. Emerg Infect Dis 2010, 16:297-300.
6. Quinn H.E., Snelling T.L., Macartney K.K., McIntyre P.B. Duration of protection after first dose of acellular pertussis vaccine in infants. Pediatrics 2014, 133:e513-e519.
7. Mooi F.R. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infect Genet Evol 2010, 10:36-49.
8. Cherry J.D. Pertussis: challenges today and for the future. PLoS pathog 2013, 9:e1003418.
9. Mooi F.R., Van Der Maas N.A., De Melker H.E. Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin. Epidemiol Infect 2014, 142:685-694.
10. Bart M.J., Harris S.R., Advani A., Arakawa Y., Bottero D., Bouchez V., et al. Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. mBio 2014, 5:e01074.
11. Mooi F.R., van Loo I.H., van Gent M., He Q., Bart M.J., Heuvelman K.J., et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis 2009, 15:1206-1213.
12. Octavia S., Maharjan R.P., Sintchenko V., Stevenson G., Reeves P.R., Gilbert G.L., et al. Insight into evolution of Bordetella pertussis from comparative genomic analysis: evidence of vaccine-driven selection. Mol Biol Evol 2011, 28:707-715.
13. Lam C., Octavia S., Bahrame Z., Sintchenko V., Gilbert G.L., Lan R. Selection and emergence of pertussis toxin promoter ptxP3 allele in the evolution of Bordetella pertussis. Infect Genet Evol 2012, 12:492-495.
14. Spokes P.J., Quinn H.E., McAnulty J.M. Review of the 2008-2009 pertussis epidemic in NSW: notifications and hospitalisations. New South Wales Public Health Bull 2010, 21:167-173.
15. Pillsbury A., Quinn H.E., McIntyre P.B. Australian vaccine preventable disease epidemiological review series: pertussis, 2006-2012. Communicable Dis Intell Quart Rep 2014, 38:E179-E194.
16. Lam C., Octavia S., Ricafort L., Sintchenko V., Gilbert G.L., Wood N., et al. Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia. Emerg Infect Dis 2014, 20:626-633.
17. Bouchez V., Brun D., Cantinelli T., Dore G., Njamkepo E., Guiso N. First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin. Vaccine 2009, 27:6034-6041.
18. Otsuka N., Han H.J., Toyoizumi-Ajisaka H., Nakamura Y., Arakawa Y., Shibayama K., et al. Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan. PloS one 2012, 7:e31985.
19. Barkoff A.M., Mertsola J., Guillot S., Guiso N., Berbers G., He Q. Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland. Clin Vaccine Immunol 2012, 19:1703-1704.
20. Pawloski L.C., Queenan A.M., Cassiday P.K., Lynch A.S., Harrison M.J., Shang W., et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States. Clin Vaccine Immunol 2014, 21:119-125.
21. Martin S.W., Pawloski L., Williams M., Weening K., DeBolt C., Qin X., et al. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage. Clin Infect DisV 60 2015, 223-227.
22. Melvin J.A., Scheller E.V., Miller J.F., Cotter P.A. Bordetella pertussis pathogenesis: current and future challenges. Nat Rev Microbiol 2014, 12:274-288.
23. Leininger E., Roberts M., Kenimer J.G., Charles I.G., Fairweather N., Novotny P., et al. Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells. Proc Natl Acad Sci US A 1991, 88:345-349.
24. van Gent M., van Loo I.H., Heuvelman K.J., de Neeling A.J., Teunis P., Mooi F.R. Studies on Prn variation in the mouse model and comparison with epidemiological data. PloS one 2011, 6:e18014.
25. Inatsuka C.S., Xu Q., Vujkovic-Cvijin I., Wong S., Stibitz S., Miller J.F., et al. Pertactin is required for Bordetella species to resist neutrophil-mediated clearance. Infect Immun 2010, 78:2901-2909.
26. de Gouw D., de Jonge M.I., Hermans P.W., Wessels H.J., Zomer A., Berends A., et al. Proteomics-identified Bvg-activated autotransporters protect against Bordetella pertussis in a mouse model. PloS one 2014, 9:e105011.
27. Li H., Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009, 25:1754-1760.
28. Poolman J.T., Hallander H.O. Acellular pertussis vaccines and the role of pertactin and fimbriae. Expert Rev Vaccines 2007, 6:47-56.
29. WHO. Pertussis vaccines: WHO position paper-August 2015. Weekly epidemiological record2015. p. 433-60.
30. Fedele G., Bianco M., Ausiello C.M. The virulence factors of Bordetella pertussis: talented modulators of host immune response. Arch Immunol Ther Exp 2013, 61:445-457.
31. Hegerle N., Dore G., Guiso N. Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine. Vaccine 2014, 32:6597-6600.
32. Polak M., Zawadka M., Mosiej E., Rabczenko D., Augustynowicz E., Guiso N., et al. Colonization of Bordetella pertussis clinical isolates that differ by pulsed field gel electrophoresis types in the lungs of naive mice or mice immunized with the whole-cell pertussis vaccine used in Poland. Arch Immunol Ther Exp 2015, 63:155-160.
33. Boursaux-Eude C., Thiberge S., Carletti G., Guiso N. Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine. Vaccine 1999, 17:2651-2660.
34. Guiso N., Capiau C., Carletti G., Poolman J., Hauser P. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine 1999, 17:2366-2376.